

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claim 1 (Currently Amended) A polypeptide having at least 80% identity to SEQ ID NO: 1 mutant *Neisseria meningitidis* ADP-ribosylating enzyme, wherein the polypeptide mutant has a substitution at one or more of amino acids corresponding to Glu-109, Glu-111 or Glu-120 of SEQ ID NO: 1.

Claim 2 (Currently Amended) The polypeptide mutant enzyme of claim 1, wherein the polypeptide mutant has reduced or eliminated ADP ribosyltransferase and/or NAD-glycohydrolase activity relative to the wild-type enzyme, wherein the wild-type enzyme has amino acid sequence SEQ ID NO: 1.

Claim 3 (Currently Amended) The polypeptide mutant enzyme of claim 1 or claim 2, wherein the substitution is Glu to Asp.

Claim 4 (Currently Amended) The polypeptide mutant enzyme of claim 1, wherein the polypeptide enzyme comprises one of the amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.

Claim 5 (Currently Amended) A polypeptide protein comprising a fragment of a polypeptide having at least 80% identity to SEQ ID NO: 1 α-*Neisseria meningitidis* ADP-ribosylating protein, wherein (i) the fragment includes one or more of amino acids corresponding to Glu-109, Glu-111 or Glu-120 from said polypeptide ADP-ribosylating protein, and (ii) one or more of said amino acids corresponding to Glu-109, Glu-111 or Glu-120 is substituted.

Claim 6 (Currently Amended) The polypeptide protein of claim 5, wherein the amino acid corresponding to Glu-109, Glu-111 or Glu-120 is substituted with Asp.

Claim 7 (Currently Amended) The polypeptide protein of claim 6 or claim 7, wherein the fragment comprises at least 7 consecutive amino acids from the polypeptide toxin or mutant toxin.

Claim 8 (Canceled).

Claim 9 (Currently Amended) The polypeptide protein of claim 6 in admixture with a second antigen.

Claim 10 (Canceled).

Claim 11 (Currently Amended) An immunogenic composition comprising the polypeptide protein of claim 1 in admixture with a second antigen.

Claims 12-13 (Canceled).

Claim 14 (Withdrawn-currently amended) A method of treating a patient, comprising administering a therapeutically effective amount of the polypeptide protein of claims 1, 2, 4, 5, or 6.

Claim 15 (Canceled).